EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.
Also called NCT03932721
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose diagnostic
- Phase
- Phase 4
- Enrolled
- 110 participants
- Sponsor
- University of Campinas, Brazil
- Registry
-
NCT03932721
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Brazil
- Registry status
- Completed
Technical summary
Registry record NCT03932721. Randomized; single masking; primary purpose diagnostic. Start 2018-10-01 (actual); primary completion 2021-06-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial
- Acronym
- EXCEED-BHS3
- Condition
- Dyslipidemia Associated With Type II Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Hypertension Arterial
- Intervention (Drug)
- Evolocumab 140 MG/ML
- Lead sponsor
- University of Campinas, Brazil
Record details
- Record id
cardio:ct-nct03932721- Content hash
7980ed1370b3d91b90ebcee7919a649904b67489ca5aeeb741cb0c037ad02977